1.1 A bill for an act
1.2 relating to health insurance; requiring coverage of vasectomies by health plans;
1.3 amending Minnesota Statutes 2024, section 62Q.522, subdivision 1.
1.4BE IT ENACTED BY THE LEGISLATURE OF THE STATE OF MINNESOTA:
1.5 Section 1. Minnesota Statutes 2024, section 62Q.522, subdivision 1, is amended to read:
1.6 Subdivision 1.Definitions.(a) The definitions in this subdivision apply to this section.
1.7 (b) "Contraceptive method" means a drug, device, or other product approved by the
1.8Food and Drug Administration to prevent unintended pregnancy.
1.9 (c) "Contraceptive service" means consultation, examination, procedures, and medical
1.10services related to the prevention of unintended pregnancy, excluding vasectomies. This
1.11includes but is not limited to voluntary sterilization procedures, patient education, counseling
1.12on contraceptives, and follow-up services related to contraceptive methods or services,
1.13management of side effects, counseling for continued adherence, and device insertion or
1.14removal.
1.15 (d) "Medical necessity" includes but is not limited to considerations such as severity of
1.16side effects, difference in permanence and reversibility of a contraceptive method or service,
1.17and ability to adhere to the appropriate use of the contraceptive method or service, as
1.18determined by the attending provider.
1.19 (e) "Therapeutic equivalent version" means a drug, device, or product that can be expected
1.20to have the same clinical effect and safety profile when administered to a patient under the
1.21conditions specified in the labeling, and that:
1.22 (1) is approved as safe and effective;
1Section 1.
REVISOR RSI/NS 25-0134512/19/24
State of Minnesota
This Document can be made available
in alternative formats upon request
HOUSE OF REPRESENTATIVES
H. F. No. 774
NINETY-FOURTH SESSION
Authored by Hemmingsen-Jaeger and Feist02/13/2025
The bill was read for the first time and referred to the Committee on Commerce Finance and Policy 2.1 (2) is a pharmaceutical equivalent: (i) containing identical amounts of the same active
2.2drug ingredient in the same dosage form and route of administration; and (ii) meeting
2.3compendial or other applicable standards of strength, quality, purity, and identity;
2.4 (3) is bioequivalent in that:
2.5 (i) the drug, device, or product does not present a known or potential bioequivalence
2.6problem and meets an acceptable in vitro standard; or
2.7 (ii) if the drug, device, or product does present a known or potential bioequivalence
2.8problem, it is shown to meet an appropriate bioequivalence standard;
2.9 (4) is adequately labeled; and
2.10 (5) is manufactured in compliance with current manufacturing practice regulations.
2.11 EFFECTIVE DATE.This section is effective January 1, 2026, and applies to health
2.12plans offered, issued, or renewed on or after that date.
2Section 1.
REVISOR RSI/NS 25-0134512/19/24